“…The TRAQ 4.1, a disease-neutral measure, was used in six studies with AYA with a single disease population: congenital heart disease/pediatric heart transplantation [3,12,13,15,16], cystic fibrosis [17], and childhood cancer survival [18]; and in three studies with a diverse sample of conditions ranging from four specified conditions [14] to 11 specified conditions [2]. The TRAQ 5.0 was used in five studies with AYA with a single condition, including chronic rheumatology conditions [19], diabetes [22,24], inflammatory bowel disease [23], and spina bifida [25]. The STARx was used with one disease-specific population, eosinophilic esophagitis and gastroenteritis [29].…”